Vol 53, No 5 (2019)
Letter to the Editors
Published online: 2019-10-23
‘Falling off’ the dopamine wagon
Abstract
Not available
Keywords: Parkinson’s diseasefracturelevodopaneurodegenerative disease
References
- Nojszewska M, Potulska-Chromik A, Jamrozik Z, et al. Electrophysiological and clinical assessment of dysautonomia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP): a comparative study. Neurol Neurochir Pol. 2019; 53(1): 26–33.
- van Gerpen JA, Al-Shaikh RH, Tipton PW, et al. Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension. Neurology. 2019; 93(14): e1339–e1347.
- Johnell O, Melton LJ, Atkinson EJ, et al. Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing. 1992; 21(1): 32–38.
- Genever RW, Downes TW, Medcalf P. Fracture rates in Parkinson's disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing. 2005; 34(1): 21–24.
- Melton LJ, Leibson CL, Achenbach SJ, et al. Fracture risk after the diagnosis of Parkinson's disease: Influence of concomitant dementia. Mov Disord. 2006; 21(9): 1361–1367.
- Newmark HL, Newmark J. Vitamin D and Parkinson's disease--a hypothesis. Mov Disord. 2007; 22(4): 461–468.
- Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018; 33(3): 372–390.
- Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002; 14(2): 223–36; discussion 222.
- Rahman S, Griffin HJ, Quinn NP, et al. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord. 2008; 23(10): 1428–1434.
